FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Overcoming Barriers in Parkinson’s Disease Trial & Endpoint Development Through Statistics

Overcoming Barriers in Parkinson’s Disease Trial & Endpoint Development Through Statistics

By | 17 September 2025

Designing smarter clinical trials for slowly progressing Parkinson’s populations, reducing operational hurdles while improving feasibility and signal detection
Optimizing endpoint selection with robust statistical frameworks that reflect disease biology and patient reality, supporting regulatory and clinical confidence
Enabling sponsors to run faster, leaner, and more conclusive studies that unlock disease-modifying therapies for patients sooner

VIRTUAL